{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:30:53Z","timestamp":1789637453354,"version":"4.0.0"},"reference-count":347,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"am","delay-in-days":287,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL093242"],"award-info":[{"award-number":["R01HL093242"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL133216"],"award-info":[{"award-number":["R01HL133216"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL137229"],"award-info":[{"award-number":["R01HL137229"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL156362"],"award-info":[{"award-number":["R01HL156362"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.vph.2023.107249","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T12:27:05Z","timestamp":1701952025000},"page":"107249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis"],"prefix":"10.1016","volume":"154","author":[{"given":"Bo","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Eisa-Beygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane R.","family":"Bielenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0015","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/hep.30946","article-title":"The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH","volume":"70","author":"Loomba","year":"2019","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.vph.2023.107249_bb0020","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0025","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.vph.2023.107249_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.742382","article-title":"Non-alcoholic steatohepatitis pathogenesis, diagnosis, and treatment","volume":"8","author":"Zhu","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/flgastro-2013-100403","article-title":"Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging","volume":"5","author":"Dyson","year":"2014","journal-title":"Frontline Gastroenterol."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cld.740","article-title":"Con: liver biopsy remains the gold standard to evaluate fibrosis in patients with nonalcoholic fatty liver disease","volume":"13","author":"Berger","year":"2019","journal-title":"Clin. Liver Dis. (Hoboken)"},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0050","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0055","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/liv.14478","article-title":"What's in a name? Renaming 'NAFLD' to 'MAFLD'","volume":"40","author":"Fouad","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.vph.2023.107249_bb0060","series-title":"Atherosclerosis, StatPearls, Treasure Island (FL) Ineligible Companies. Disclosure: Ishwarlal Jialal Declares No Relevant Financial Relationships with Ineligible Companies","author":"Pahwa","year":"2023"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041136","article-title":"Cardiovascular risk factors in childhood and adolescence","volume":"11","author":"Wacker-Gussmann","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.vph.2023.107249_bb0070","series-title":"Endotext, South Dartmouth (MA)","article-title":"The role of lipids and lipoproteins in atherosclerosis","author":"Linton","year":"2000"},{"key":"10.1016\/j.vph.2023.107249_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/634983","article-title":"Rapid progression of coronary atherosclerosis: a review","volume":"2015","author":"Shah","year":"2015","journal-title":"Thrombosis"},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb0080","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1586\/erc.11.120","article-title":"Symptomatic and asymptomatic carotid artery plaque","volume":"9","author":"Mughal","year":"2011","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"issue":"12","key":"10.1016\/j.vph.2023.107249_bb0085","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of plaque formation and rupture","volume":"114","author":"Bentzon","year":"2014","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0090","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrd3444","article-title":"Anti-inflammatory therapeutics for the treatment of atherosclerosis","volume":"10","author":"Charo","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0095","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1160\/TH08-07-0469","article-title":"Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes","volume":"101","author":"Newby","year":"2009","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications","volume":"51","author":"Fabbrini","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0105","first-page":"504","article-title":"Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity","volume":"11","author":"Henning","year":"2021","journal-title":"Am. J. Cardiovasc. Dis."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4103\/ijem.IJEM_585_17","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"22","author":"Dharmalingam","year":"2018","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051835","article-title":"The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation","volume":"21","author":"Poznyak","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb0120","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: an update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/0976-9668.149117","article-title":"Association of atherosclerosis with dyslipidemia and co-morbid conditions: a descriptive study","volume":"6","author":"Garg","year":"2015","journal-title":"J. Nat. Sci. Biol. Med."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001850","article-title":"Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis","volume":"8","author":"Wong","year":"2021","journal-title":"Open Heart"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0135","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/apt.17617","article-title":"Systematic review and meta-analysis: association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease","volume":"58","author":"Jamalinia","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2023.107249_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.767314","article-title":"Current and potential therapies targeting inflammation in NASH","volume":"12","author":"Albhaisi","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0145","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0150","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2174\/1871530322666211220110810","article-title":"Hepatic lipid metabolism disorder and atherosclerosis","volume":"22","author":"Zhang","year":"2022","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0155","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1194\/jlr.M500322-JLR200","article-title":"LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice","volume":"47","author":"Kypreos","year":"2006","journal-title":"J. Lipid Res."},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb0160","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1161\/ATVBAHA.116.306874","article-title":"Do the Apoe\u2212\/\u2212 and Ldlr\u2212\/\u2212 mice yield the same insight on atherogenesis?","volume":"36","author":"Getz","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"11","key":"10.1016\/j.vph.2023.107249_bb0165","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/labinvest.2014.112","article-title":"Western diet in ApoE-LDLR double-deficient mouse model of atherosclerosis leads to hepatic steatosis, fibrosis, and tumorigenesis","volume":"94","author":"Kampschulte","year":"2014","journal-title":"Lab. Investig."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030668","article-title":"LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease","volume":"7","author":"Bieghs","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2023.107249_bb0175","doi-asserted-by":"crossref","first-page":"12931","DOI":"10.1038\/srep12931","article-title":"Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis","volume":"5","author":"Schierwagen","year":"2015","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb0180","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/ATVBAHA.110.219659","article-title":"Sterol regulatory element-binding protein-1 determines plasma remnant lipoproteins and accelerates atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"31","author":"Karasawa","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"38","key":"10.1016\/j.vph.2023.107249_bb0185","doi-asserted-by":"crossref","first-page":"36652","DOI":"10.1074\/jbc.M306540200","article-title":"Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver","volume":"278","author":"Horton","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb0190","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4254\/wjh.v7.i8.1012","article-title":"Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease","volume":"7","author":"Souza-Mello","year":"2015","journal-title":"World J. Hepatol."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062061","article-title":"PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice","volume":"21","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb0200","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI11497","article-title":"PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice","volume":"107","author":"Tordjman","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0205","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.1038\/s41598-020-63579-3","article-title":"Hepatocyte-specific deletion of Pparalpha promotes NAFLD in the context of obesity","volume":"10","author":"Regnier","year":"2020","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb0210","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1194\/jlr.M300030-JLR200","article-title":"Stimulation of cholesterol synthesis and hepatic lipogenesis in patients with severe malabsorption","volume":"44","author":"Cachefo","year":"2003","journal-title":"J. Lipid Res."},{"issue":"11","key":"10.1016\/j.vph.2023.107249_bb0215","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1161\/ATVBAHA.118.311664","article-title":"Myeloid HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase determines atherosclerosis by modulating migration of macrophages","volume":"38","author":"Sakai","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0220","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bbalip.2011.09.017","article-title":"Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger?","volume":"1821","author":"Jensen-Urstad","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"30","key":"10.1016\/j.vph.2023.107249_bb0225","doi-asserted-by":"crossref","first-page":"23398","DOI":"10.1074\/jbc.M110.100321","article-title":"Macrophage fatty-acid synthase deficiency decreases diet-induced atherosclerosis","volume":"285","author":"Schneider","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0230","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cmet.2017.08.011","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab."},{"issue":"47","key":"10.1016\/j.vph.2023.107249_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq1984","article-title":"Macrophage acetyl-CoA carboxylase regulates acute inflammation through control of glucose and lipid metabolism","volume":"8","author":"Yeudall","year":"2022","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0240","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jhep.2017.12.012","article-title":"Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: an observational cohort study","volume":"68","author":"Lee","year":"2018","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0245","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12020-012-9712-1","article-title":"Assessment of endothelial function in patients with nonalcoholic fatty liver disease","volume":"43","author":"Colak","year":"2013","journal-title":"Endocrine"},{"issue":"12","key":"10.1016\/j.vph.2023.107249_bb0250","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/heartjnl-2013-305099","article-title":"Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population","volume":"100","author":"Kim","year":"2014","journal-title":"Heart"},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb0255","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1161\/ATVBAHA.112.252957","article-title":"Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese","volume":"32","author":"Huang","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0260","first-page":"7673","article-title":"Association between nonalcoholic fatty liver disease and carotid atherosclerosis: a meta-analysis","volume":"8","author":"Cai","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0265","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jc.2015-3111","article-title":"Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD","volume":"101","author":"Bril","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0270","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/gutjnl-2017-315691","article-title":"Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation","volume":"67","author":"Ibrahim","year":"2018","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0275","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0280","doi-asserted-by":"crossref","first-page":"15938","DOI":"10.1038\/s41598-021-95581-8","article-title":"Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease","volume":"11","author":"Arai","year":"2021","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb0285","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.vph.2023.107249_bb0290","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.2967\/jnumed.107.038661","article-title":"Role of inflammation in atherosclerosis","volume":"48","author":"Spagnoli","year":"2007","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0295","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcmgh.2020.08.012","article-title":"Roles of CCR2 and CCR5 for hepatic macrophage polarization in mice with liver parenchymal cell-specific NEMO deletion","volume":"11","author":"Bartneck","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0300","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1172\/JCI28549","article-title":"Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques","volume":"117","author":"Tacke","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0305","doi-asserted-by":"crossref","first-page":"G1324","DOI":"10.1152\/ajpgi.90564.2008","article-title":"Interleukin-1 participates in the progression from liver injury to fibrosis","volume":"296","author":"Gieling","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.vph.2023.107249_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589654","article-title":"Targeting IL-1beta in the treatment of atherosclerosis","volume":"11","author":"Mai","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0315","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0320","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","article-title":"IL-6 pathway in the liver: from physiopathology to therapy","volume":"64","author":"Schmidt-Arras","year":"2016","journal-title":"J. Hepatol."},{"issue":"22","key":"10.1016\/j.vph.2023.107249_bb0325","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1161\/01.CIR.0000148135.08582.97","article-title":"Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis","volume":"110","author":"Schieffer","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0330","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40139-015-0093-z","article-title":"TNFalpha in liver fibrosis","volume":"3","author":"Yang","year":"2015","journal-title":"Curr. Pathobiol. Rep."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0335","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41419-020-2411-6","article-title":"TNF-receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice","volume":"11","author":"Wandrer","year":"2020","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0340","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202000764R","article-title":"A strategy to prevent atherosclerosis via TNF receptor regulation","volume":"35","author":"Kim","year":"2021","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0345","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cardiores.2005.01.001","article-title":"Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice","volume":"66","author":"Boesten","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2023.107249_bb0350","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.matbio.2015.01.004","article-title":"Matrix metalloproteinases in liver injury, repair and fibrosis","volume":"44-46","author":"Duarte","year":"2015","journal-title":"Matrix Biol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0355","doi-asserted-by":"crossref","first-page":"23081","DOI":"10.1038\/s41598-021-02508-4","article-title":"Disparate effects of MMP and TIMP modulation on coronary atherosclerosis and associated myocardial fibrosis","volume":"11","author":"Kremastiotis","year":"2021","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.vph.2023.107249_bb0360","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3748\/wjg.v12.i19.3044","article-title":"Correlation between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models","volume":"12","author":"Nie","year":"2006","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0365","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0021-9150(03)00251-X","article-title":"Different expression of MMPs\/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed","volume":"170","author":"Orbe","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2023.107249_bb0370","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.matbio.2017.12.012","article-title":"Matrix metalloproteinases and liver fibrosis (translational aspects)","volume":"68-69","author":"Roeb","year":"2018","journal-title":"Matrix Biol."},{"issue":"11","key":"10.1016\/j.vph.2023.107249_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113946","article-title":"Matrix metalloproteinases as biomarkers of atherosclerotic plaque instability","volume":"21","author":"Olejarz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0380","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2016.06.001","article-title":"Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis","volume":"151","author":"Sinn","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0385","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jhep.2008.05.024","article-title":"Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies","volume":"49","author":"Kadayifci","year":"2008","journal-title":"J. Hepatol."},{"issue":"16","key":"10.1016\/j.vph.2023.107249_bb0390","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1161\/CIRCULATIONAHA.114.009278","article-title":"Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study","volume":"130","author":"An","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb0395","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/eci.12777","article-title":"High burden of coronary atherosclerosis in patients with cirrhosis","volume":"47","author":"Kazankov","year":"2017","journal-title":"Eur. J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0400","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000023","article-title":"Liver stiffness measurement with FibroScan: use the right probe in the right conditions!","volume":"10","author":"Berger","year":"2019","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb0405","article-title":"Liver stiffness is associated with the burden of carotid and systemic atherosclerosis in an unorganized cohort of patients 40-64 years old","volume":"12","author":"Kuznetsova","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.vph.2023.107249_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.707529","article-title":"Role of lipid accumulation and inflammation in atherosclerosis: focus on molecular and cellular mechanisms","volume":"8","author":"Malekmohammad","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"14","key":"10.1016\/j.vph.2023.107249_bb0415","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/CIRCULATIONAHA.122.061010","article-title":"Low-density lipoprotein cholesterol is predominantly associated with atherosclerotic cardiovascular disease events in patients with evidence of coronary atherosclerosis: the Western Denmark heart registry","volume":"147","author":"Mortensen","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2023.107249_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7555\/JBR.27.20120077","article-title":"Lipoprotein metabolism in nonalcoholic fatty liver disease","volume":"27","author":"Jiang","year":"2013","journal-title":"J. Biomed. Res."},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb0430","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/01.ATV.0000092328.66882.F5","article-title":"Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor","volume":"23","author":"Moore","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0435","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2119\/molmed.2012.00113","article-title":"Apolipoprotein A-I modulates processes associated with diet-induced nonalcoholic fatty liver disease in mice","volume":"18","author":"Karavia","year":"2012","journal-title":"Mol. Med."},{"issue":"18","key":"10.1016\/j.vph.2023.107249_bb0440","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202101034","article-title":"Apolipoprotein A4 restricts diet-induced hepatic steatosis via SREBF1-mediated lipogenesis and enhances IRS-PI3K-Akt signaling","volume":"66","author":"Cheng","year":"2022","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.vph.2023.107249_bb0445","doi-asserted-by":"crossref","first-page":"134","DOI":"10.12688\/f1000research.9845.1","article-title":"Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease","volume":"6","author":"Shapiro","year":"2017","journal-title":"F1000Res."},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb0450","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1172\/JCI86028","article-title":"Inhibition of apolipoprotein B synthesis stimulates endoplasmic reticulum autophagy that prevents steatosis","volume":"126","author":"Conlon","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2023.107249_bb0455","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1194\/jlr.R800070-JLR200","article-title":"Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond","volume":"50 Suppl(Suppl)","author":"Pendse","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.vph.2023.107249_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117601","article-title":"ApoE deficiency promotes non-alcoholic fatty liver disease in mice via impeding AMPK\/mTOR mediated autophagy","volume":"252","author":"Lu","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.vph.2023.107249_bb0465","article-title":"The atherogenic index of plasma: a novel factor more closely related to non-alcoholic fatty liver disease than other lipid parameters in adults","volume":"9","author":"Liu","year":"2022","journal-title":"Front. Nutr."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0470","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.arcmed.2019.08.009","article-title":"Atherogenic index of plasma: novel predictive biomarker for cardiovascular illnesses","volume":"50","author":"Fernandez-Macias","year":"2019","journal-title":"Arch. Med. Res."},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb0475","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092101","article-title":"Atherogenic index of plasma in non-alcoholic fatty liver disease: systematic review and meta-analysis","volume":"10","author":"Ismaiel","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0480","article-title":"Atherogenic index of plasma (AIP) and its association with fatty liver in obese adolescents","volume":"10","author":"Dag","year":"2023","journal-title":"Children (Basel)"},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0485","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40001-022-00731-x","article-title":"Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes","volume":"27","author":"Samimi","year":"2022","journal-title":"Eur. J. Med. Res."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0490","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12944-020-01319-2","article-title":"The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study","volume":"19","author":"Dong","year":"2020","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.vph.2023.107249_bb0495","article-title":"Association between the atherogenic index of plasma and new-onset non-alcoholic fatty liver disease in non-obese participants","volume":"13","author":"Li","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0500","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000215722","article-title":"Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone","volume":"18","author":"Yener","year":"2009","journal-title":"Med. Princ. Pract."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0505","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.atherosclerosis.2009.10.011","article-title":"Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease","volume":"209","author":"Sookoian","year":"2010","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0510","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","article-title":"Immunity and inflammation in atherosclerosis","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ. Res."},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb0515","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/01.ATV.20.7.1716","article-title":"Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection","volume":"20","author":"Carr","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb0520","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2023.107249_bb0525","doi-asserted-by":"crossref","first-page":"7434376","DOI":"10.1155\/2019\/7434376","article-title":"The role of monocytes and macrophages in human atherosclerosis, plaque neoangiogenesis, and atherothrombosis","volume":"2019","author":"Moroni","year":"2019","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0530","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12967-018-1587-3","article-title":"MRI of atherosclerosis and fatty liver disease in cholesterol fed rabbits","volume":"16","author":"Taylor","year":"2018","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0535","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2011.08.041","article-title":"NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages","volume":"220","author":"Bieghs","year":"2012","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0540","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1038\/s41598-022-09256-z","article-title":"Improving the accuracy and robustness of carotid-femoral pulse wave velocity measurement using a simplified tube-load model","volume":"12","author":"Xu","year":"2022","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0545","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/01.HYP.37.5.1236","article-title":"Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients","volume":"37","author":"Laurent","year":"2001","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0550","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.atherosclerosis.2014.10.004","article-title":"Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness","volume":"237","author":"Sunbul","year":"2014","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0555","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.atherosclerosis.2015.04.009","article-title":"Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men","volume":"240","author":"Ozturk","year":"2015","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0560","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.atherosclerosis.2015.05.002","article-title":"Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease","volume":"241","author":"Chen","year":"2015","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17040460","article-title":"NAFLD and increased aortic stiffness: parallel or common physiopathological mechanisms?","volume":"17","author":"Villela-Nogueira","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb0570","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/liv.12994","article-title":"Increasing aortic stiffness is predictive of advanced liver fibrosis in patients with type 2 diabetes: the Rio-T2DM cohort study","volume":"36","author":"Leite","year":"2016","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0575","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","article-title":"Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology","volume":"17","author":"Eslam","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/cells9041041","article-title":"The emerging role of MicroRNAs in NAFLD: highlight of MicroRNA-29a in modulating oxidative stress, inflammation, and beyond","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"issue":"22","key":"10.1016\/j.vph.2023.107249_bb0585","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225547","article-title":"MicroRNAs as potential biomarkers in atherosclerosis","volume":"20","author":"Churov","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0590","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12986-021-00552-5","article-title":"A comprehensive review of long non-coding RNAs in the pathogenesis and development of non-alcoholic fatty liver disease","volume":"18","author":"Shabgah","year":"2021","journal-title":"Nutr. Metab. (Lond.)"},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb0595","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1161\/ATVBAHA.120.314222","article-title":"Long noncoding RNAs in atherosclerosis and vascular injury: pathobiology, biomarkers, and targets for therapy","volume":"40","author":"Pierce","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0600","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.vph.2023.107249_bb0605","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/191823","article-title":"Atherosclerosis, dyslipidemia, and inflammation: the significant role of polyunsaturated fatty acids","volume":"2013","author":"Dessi","year":"2013","journal-title":"ISRN Inflamm."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0610","first-page":"109","article-title":"Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction","volume":"4","author":"Basaranoglu","year":"2015","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb0615","doi-asserted-by":"crossref","DOI":"10.3390\/nu15071740","article-title":"Carbohydrate intake and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies","volume":"15","author":"Jo","year":"2023","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0620","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: a major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J. Hepatol."},{"issue":"28","key":"10.1016\/j.vph.2023.107249_bb0625","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.3748\/wjg.v20.i28.9330","article-title":"Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations","volume":"20","author":"Milic","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"21","key":"10.1016\/j.vph.2023.107249_bb0630","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0635","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","article-title":"Total body weight loss of >\/= 10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis","volume":"60","author":"Glass","year":"2015","journal-title":"Dig. Dis. Sci."},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb0640","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1161\/CIRCULATIONAHA.109.879254","article-title":"Dietary intervention to reverse carotid atherosclerosis","volume":"121","author":"Shai","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0645","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0650","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","article-title":"Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways","volume":"60","author":"Koushki","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0655","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jacc.2021.10.035","article-title":"Coronary atherosclerotic plaque regression: JACC state-of-the-art review","volume":"79","author":"Dawson","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0660","doi-asserted-by":"crossref","DOI":"10.3390\/diseases6040087","article-title":"Judicious use of lipid lowering agents in the management of NAFLD","volume":"6","author":"Iqbal","year":"2018","journal-title":"Diseases"},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0665","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.dld.2014.07.170","article-title":"The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease","volume":"47","author":"Pastori","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.vph.2023.107249_bb0670","author":"Talreja","year":"2023"},{"issue":"12","key":"10.1016\/j.vph.2023.107249_bb0675","first-page":"MS6","article-title":"Safety and efficacy of combined ezetimibe\/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease","volume":"15","author":"Abel","year":"2009","journal-title":"Med. Sci. Monit."},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb0680","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0685","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3892\/etm.2021.10251","article-title":"Efficacy of simvastatin on carotid atherosclerotic plaque and its effects on serum inflammatory factors and cardiocerebrovascular events in elderly patients","volume":"22","author":"Zhang","year":"2021","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0690","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/ajg.2010.299","article-title":"Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis heart study randomized clinical trial","volume":"106","author":"Foster","year":"2011","journal-title":"Am. J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.vph.2023.107249_bb0695","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/j.1365-2036.2006.02926.x","article-title":"A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients","volume":"23","author":"Gomez-Dominguez","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2023.107249_bb0700","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fphar.2018.00438","article-title":"Atorvastatin inhibits inflammatory response, attenuates lipid deposition, and improves the stability of vulnerable atherosclerotic plaques by modulating autophagy","volume":"9","author":"Peng","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0705","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2004.01.008","article-title":"Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study","volume":"174","author":"Rallidis","year":"2004","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb0710","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520932816","article-title":"Pravastatin attenuates atherosclerosis after myocardial infarction by inhibiting inflammatory Ly6C(high) monocytosis in apolipoprotein E knockout mice","volume":"48","author":"Chen","year":"2020","journal-title":"J. Int. Med. Res."},{"issue":"11","key":"10.1016\/j.vph.2023.107249_bb0715","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1872-034X.2011.00849.x","article-title":"Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study","volume":"41","author":"Hyogo","year":"2011","journal-title":"Hepatol. Res."},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb0720","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138047","article-title":"Pitavastatin reduces inflammation in atherosclerotic plaques in apolipoprotein E-deficient mice with late stage renal disease","volume":"10","author":"Shibasaki","year":"2015","journal-title":"PLoS One"},{"issue":"93","key":"10.1016\/j.vph.2023.107249_bb0725","first-page":"1117","article-title":"Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis","volume":"56","author":"Mihaila","year":"2009","journal-title":"Hepatogastroenterology"},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb0730","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00044011-200727090-00001","article-title":"Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review","volume":"27","author":"Frisinghelli","year":"2007","journal-title":"Clin. Drug Investig."},{"issue":"25","key":"10.1016\/j.vph.2023.107249_bb0735","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0740","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12967-021-02727-3","article-title":"Rosuvastatin exerts anti-atherosclerotic effects by improving macrophage-related foam cell formation and polarization conversion via mediating autophagic activities","volume":"19","author":"Zhang","year":"2021","journal-title":"J. Transl. Med."},{"issue":"19","key":"10.1016\/j.vph.2023.107249_bb0745","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0750","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fernandez-Miranda","year":"2008","journal-title":"Dig. Liver Dis."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0755","first-page":"376","article-title":"Anti-inflammatory role of fenofibrate in treating diseases","volume":"23","author":"Jin","year":"2023","journal-title":"Biomol. Biomed."},{"key":"10.1016\/j.vph.2023.107249_bb0760","article-title":"Fenofibrate improves insulin resistance and hepatic steatosis and regulates the Let-7\/SERCA2b axis in high-fat diet-induced non-alcoholic fatty liver disease mice","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0765","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","article-title":"Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study","volume":"22","author":"Athyros","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0770","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2006.02.036","article-title":"Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI","volume":"190","author":"Corti","year":"2007","journal-title":"Atherosclerosis"},{"issue":"9260","key":"10.1016\/j.vph.2023.107249_bb0775","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study","volume":"357","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0780","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0785","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1210\/jc.2009-2622","article-title":"Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease","volume":"95","author":"Fabbrini","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2023.107249_bb0790","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.12659\/MSM.895547","article-title":"Niacin suppresses progression of atherosclerosis by inhibiting vascular inflammation and apoptosis of vascular smooth muscle cells","volume":"21","author":"Su","year":"2015","journal-title":"Med. Sci. Monit."},{"issue":"11","key":"10.1016\/j.vph.2023.107249_bb0795","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1592\/phco.23.14.1463.31942","article-title":"Ezetimibe: a selective cholesterol absorption inhibitor","volume":"23","author":"Nutescu","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0800","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1872-034X.2010.00644.x","article-title":"Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study","volume":"40","author":"Yoneda","year":"2010","journal-title":"Hepatol. Res."},{"issue":"11","key":"10.1016\/j.vph.2023.107249_bb0805","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142430","article-title":"Ezetimibe attenuates atherosclerosis associated with lipid reduction and inflammation inhibition","volume":"10","author":"Tie","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb0810","doi-asserted-by":"crossref","DOI":"10.3390\/nu12092769","article-title":"Effects of omega-3 polyunsaturated fatty acid supplementation on non-alcoholic fatty liver: a systematic review and meta-analysis","volume":"12","author":"Lee","year":"2020","journal-title":"Nutrients"},{"issue":"9356","key":"10.1016\/j.vph.2023.107249_bb0815","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(03)12468-3","article-title":"Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial","volume":"361","author":"Thies","year":"2003","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb0820","first-page":"483","article-title":"The PCSK9 inhibitors: a novel therapeutic target enters clinical practice","volume":"8","author":"Lepor","year":"2015","journal-title":"Am. Health Drug Benefits"},{"issue":"13","key":"10.1016\/j.vph.2023.107249_bb0825","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137378","article-title":"Effects of PCSK-9 inhibition by alirocumab treatments on biliary cirrhotic rats","volume":"23","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.vph.2023.107249_bb0830","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.122.062557","article-title":"Alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: the ARCHITECT study","volume":"147","author":"Perez de Isla","year":"2023","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0835","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb0840","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb0845","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1042\/BJ20051694","article-title":"ABCA1-dependent but apoA-I-independent cholesterol efflux mediated by fatty acid-bile acid conjugates (FABACs)","volume":"396","author":"Goldiner","year":"2006","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0850","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb0855","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10215","key":"10.1016\/j.vph.2023.107249_bb0860","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0865","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/2470-7511.305419","article-title":"Bile acid and cholesterol metabolism in atherosclerotic cardiovascular disease and therapy","volume":"5","author":"Chiang","year":"2020","journal-title":"Cardiol. Plus"},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0870","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","article-title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","volume":"78","author":"Hirschfield","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0875","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2022.02.033","article-title":"A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis","volume":"77","author":"Bowlus","year":"2022","journal-title":"J. Hepatol."},{"issue":"10213","key":"10.1016\/j.vph.2023.107249_bb0880","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2023.107249_bb0885","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"issue":"10019","key":"10.1016\/j.vph.2023.107249_bb0890","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0895","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3892\/etm.2023.11948","article-title":"Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: a double-blind, randomized controlled clinical trial","volume":"25","author":"Sun","year":"2023","journal-title":"Exp. Ther. Med."},{"issue":"17","key":"10.1016\/j.vph.2023.107249_bb0900","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0905","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb0910","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12933-017-0623-6","article-title":"Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17\/Treg balance in AMPK-dependent mechanisms","volume":"16","author":"Tian","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"issue":"12","key":"10.1016\/j.vph.2023.107249_bb0915","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0920","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11051362","article-title":"Effect of semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes","volume":"11","author":"Patti","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.vph.2023.107249_bb0925","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.601290","article-title":"FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases","volume":"11","author":"Tillman","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb0930","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.vph.2023.107249_bb0935","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb0940","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0945","doi-asserted-by":"crossref","first-page":"336","DOI":"10.2337\/ds18-0020","article-title":"Metformin and type 2 diabetes prevention","volume":"31","author":"Aroda","year":"2018","journal-title":"Diabetes Spectr."},{"key":"10.1016\/j.vph.2023.107249_bb0950","doi-asserted-by":"crossref","first-page":"1027484","DOI":"10.3389\/fendo.2022.1027484","article-title":"Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: a real-world cohort study","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0955","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cvr\/cvaa171","article-title":"Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase","volume":"117","author":"Seneviratne","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0960","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005855","article-title":"Understanding contemporary use of thiazolidinediones","volume":"12","author":"Arnold","year":"2019","journal-title":"Circ. Heart Fail."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb0965","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.vph.2023.107249_bb0970","doi-asserted-by":"crossref","first-page":"1043406","DOI":"10.3389\/fcvm.2022.1043406","article-title":"Thiazolidinediones play a positive role in the vascular endothelium and inhibit plaque progression in diabetic patients with coronary atherosclerosis: a systematic review and meta-analysis","volume":"9","author":"Xue","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb0975","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","article-title":"Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review","volume":"39","author":"Jensterle","year":"2022","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb0980","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb0985","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb0990","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb0995","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5114\/ceh.2020.102173","article-title":"SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review","volume":"6","author":"Dwinata","year":"2020","journal-title":"Clin. Exp. Hepatol."},{"key":"10.1016\/j.vph.2023.107249_bb1000","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.751214","article-title":"The role of SGLT2 inhibitors in atherosclerosis: a narrative mini-review","volume":"12","author":"Pahud de Mortanges","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb1005","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/hep4.1387","article-title":"Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease","volume":"3","author":"Golabi","year":"2019","journal-title":"Hepatol. Commun."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1010","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb1015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.diabres.2012.11.025","article-title":"Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease","volume":"99","author":"Zhang","year":"2013","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb1020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023937","article-title":"Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease","volume":"6","author":"Cermelli","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb1025","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4254\/wjh.v7.i2.226","article-title":"Micro RNAs in the development of non-alcoholic fatty liver disease","volume":"7","author":"Gerhard","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.vph.2023.107249_bb1030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fmed.2020.00007","article-title":"Critical role of microRNA-21 in the pathogenesis of liver diseases","volume":"7","author":"Zhang","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb1035","article-title":"miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction","volume":"2","author":"Hu","year":"2020","journal-title":"JHEP Rep."},{"key":"10.1016\/j.vph.2023.107249_bb1040","doi-asserted-by":"crossref","first-page":"8515343","DOI":"10.1155\/2018\/8515343","article-title":"miR-26a potentially contributes to the regulation of fatty acid and sterol metabolism in vitro human HepG2 cell model of nonalcoholic fatty liver disease","volume":"2018","author":"Ali","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1045","doi-asserted-by":"crossref","first-page":"14493","DOI":"10.1038\/s41598-017-15141-x","article-title":"MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb1050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/2211536607666180531093302","article-title":"Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD)","volume":"7","author":"Jampoka","year":"2018","journal-title":"Microrna"},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb1055","doi-asserted-by":"crossref","first-page":"13450","DOI":"10.18632\/oncotarget.14561","article-title":"MiR-30c-5p ameliorates hepatic steatosis in leptin receptor-deficient (db\/db) mice via down-regulating FASN","volume":"8","author":"Fan","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb1060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17101620","article-title":"miR33a\/miR33b* and miR122 as possible contributors to hepatic lipid metabolism in obese women with nonalcoholic fatty liver disease","volume":"17","author":"Auguet","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.vph.2023.107249_bb1065","doi-asserted-by":"crossref","first-page":"13729","DOI":"10.1038\/srep13729","article-title":"Effect of miR-34a in regulating steatosis by targeting PPARalpha expression in nonalcoholic fatty liver disease","volume":"5","author":"Ding","year":"2015","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb1070","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4254\/wjh.v6.i8.613","article-title":"Circulating microRNAs in patients with non-alcoholic fatty liver disease","volume":"6","author":"Celikbilek","year":"2014","journal-title":"World J. Hepatol."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1075","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/hep.22569","article-title":"Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression","volume":"48","author":"Cheung","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1080","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.jhep.2015.07.037","article-title":"Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice","volume":"63","author":"Zhang","year":"2015","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb1085","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.10","article-title":"MiR-130a-3p attenuates activation and induces apoptosis of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis by directly targeting TGFBR1 and TGFBR2","volume":"8","author":"Wang","year":"2017","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1090","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12137","article-title":"Circulating microRNA-135a-3p in serum extracellular vesicles as a potential biological marker of non-alcoholic fatty liver disease","volume":"24","author":"Jiang","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.vph.2023.107249_bb1095","doi-asserted-by":"crossref","first-page":"16163","DOI":"10.1038\/srep16163","article-title":"MiR-146a-5p suppresses activation and proliferation of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis through directly targeting Wnt1 and Wnt5a","volume":"5","author":"Du","year":"2015","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb1100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072324","article-title":"MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice","volume":"8","author":"Miller","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.bbrc.2017.09.042","article-title":"MiR-181b regulates steatosis in nonalcoholic fatty liver disease via targeting SIRT1","volume":"493","author":"Wang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb1110","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1002\/jcb.26776","article-title":"MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease","volume":"119","author":"Xu","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"46","key":"10.1016\/j.vph.2023.107249_bb1115","doi-asserted-by":"crossref","first-page":"8140","DOI":"10.3748\/wjg.v23.i46.8140","article-title":"miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1","volume":"23","author":"Liu","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.vph.2023.107249_bb1120","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1016\/j.bbadis.2017.09.020","article-title":"MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR","volume":"1863","author":"Nie","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1125","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s12072-020-10096-0","article-title":"Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism","volume":"14","author":"Li","year":"2020","journal-title":"Hepatol. Int."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1130","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1159\/000366394","article-title":"Aberrant hepatic microRNA expression in nonalcoholic fatty liver disease","volume":"34","author":"Feng","year":"2014","journal-title":"Cell. Physiol. Biochem."},{"issue":"22","key":"10.1016\/j.vph.2023.107249_bb1135","first-page":"10072","article-title":"MicroRNA-205 ameliorates lipid accumulation in non-alcoholic fatty liver disease through targeting NEU1","volume":"23","author":"Hu","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.vph.2023.107249_bb1140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ebiom.2018.09.051","article-title":"Targeting hepatic miR-221\/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice","volume":"37","author":"Jiang","year":"2018","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb1145","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.30645","article-title":"MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes","volume":"70","author":"He","year":"2019","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.vph.2023.107249_bb1150","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.yexcr.2011.05.001","article-title":"Loss of expression of miR-335 is implicated in hepatic stellate cell migration and activation","volume":"317","author":"Chen","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb1155","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/1440-1681.12940","article-title":"Down-regulation of microRNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease","volume":"45","author":"Lei","year":"2018","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jhep.2018.08.026","article-title":"MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-kappaB-TNFalpha pathway","volume":"70","author":"Zhang","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.vph.2023.107249_bb1165","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.mce.2018.03.016","article-title":"MiR-451a attenuates free fatty acids-mediated hepatocyte steatosis by targeting the thyroid hormone responsive spot 14 gene","volume":"474","author":"Zeng","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb1170","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.18632\/aging.101766","article-title":"MALAT1\/miR-15b-5p\/MAPK1 mediates endothelial progenitor cells autophagy and affects coronary atherosclerotic heart disease via mTOR signaling pathway","volume":"11","author":"Zhu","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb1175","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3892\/ijmm.2016.2497","article-title":"MicroRNA-16 suppresses the activation of inflammatory macrophages in atherosclerosis by targeting PDCD4","volume":"37","author":"Liang","year":"2016","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1180","doi-asserted-by":"crossref","first-page":"12089","DOI":"10.1038\/s41598-017-12167-z","article-title":"MircroRNA-19a promotes vascular inflammation and foam cell formation by targeting HBP-1 in atherogenesis","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb1185","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ymthe.2018.03.005","article-title":"MicroRNA-21 and the vulnerability of atherosclerotic plaques","volume":"26","author":"Barwari","year":"2018","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb1190","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112922","article-title":"MicroRNA-22 inhibition promotes the development of atherosclerosis via targeting interferon regulator factor 5","volume":"409","author":"Wu","year":"2021","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.vph.2023.107249_bb1195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13578-018-0203-9","article-title":"miR-26a inhibits atherosclerosis progression by targeting TRPC3","volume":"8","author":"Feng","year":"2018","journal-title":"Cell Biosci."},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb1200","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20212355","article-title":"Decoding microRNA drivers in atherosclerosis","volume":"42","author":"Vartak","year":"2022","journal-title":"Biosci. Rep."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb1205","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.18632\/aging.203951","article-title":"miRNA-29a inhibits atherosclerotic plaque formation by mediating macrophage autophagy via PI3K\/AKT\/mTOR pathway","volume":"14","author":"Shao","year":"2022","journal-title":"Aging (Albany NY)"},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb1210","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/nm.3200","article-title":"MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion","volume":"19","author":"Soh","year":"2013","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1215","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/ATVBAHA.116.308916","article-title":"microRNA-33 regulates macrophage autophagy in atherosclerosis","volume":"37","author":"Ouimet","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1220","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ymthe.2019.09.008","article-title":"Macrophage miR-34a is a key regulator of cholesterol efflux and atherosclerosis","volume":"28","author":"Xu","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.vph.2023.107249_bb1225","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116664","article-title":"MicroRNA-99a-5p alleviates atherosclerosis via regulating homeobox A1","volume":"232","author":"Han","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.vph.2023.107249_bb1230","article-title":"Association of circulating microRNA-122 with presence and severity of atherosclerotic lesions","volume":"6","author":"Wang","year":"2018","journal-title":"PeerJ"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb1235","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ajpath.2011.06.016","article-title":"miR-125b regulates calcification of vascular smooth muscle cells","volume":"179","author":"Goettsch","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb1240","doi-asserted-by":"crossref","first-page":"630","DOI":"10.5152\/AnatolJCardiol.2021.56721","article-title":"MiRNA-130a promotes inflammation to accelerate atherosclerosis via the regulation of proliferator-activated receptor gamma (PPARgamma) expression","volume":"25","author":"Liu","year":"2021","journal-title":"Anatol. J. Cardiol."},{"key":"10.1016\/j.vph.2023.107249_bb1245","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153091","article-title":"MiR-135a-5p inhibits vascular smooth muscle cells proliferation and migration by inactivating FOXO1 and JAK2 signaling pathway","volume":"224","author":"Li","year":"2021","journal-title":"Pathol. Res. Pract."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1250","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1007\/s11033-022-07253-z","article-title":"miR-146a contributes to atherosclerotic plaque stability by regulating the expression of TRAF6 and IRAK-1","volume":"49","author":"Chu","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.vph.2023.107249_bb1255","doi-asserted-by":"crossref","first-page":"21789","DOI":"10.1038\/srep21789","article-title":"miR-155 acts as an anti-inflammatory factor in atherosclerosis-associated foam cell formation by repressing calcium-regulated heat stable protein 1","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1260","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/CIRCRESAHA.116.309321","article-title":"MicroRNA-181b controls atherosclerosis and aneurysms through regulation of TIMP-3 and elastin","volume":"120","author":"Di Gregoli","year":"2017","journal-title":"Circ. Res."},{"issue":"24","key":"10.1016\/j.vph.2023.107249_bb1265","first-page":"12849","article-title":"Circular RNA circHIPK3 as a novel circRNA regulator of autophagy and endothelial cell dysfunction in atherosclerosis","volume":"24","author":"Wei","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"12","key":"10.1016\/j.vph.2023.107249_bb1270","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s12033-021-00376-x","article-title":"Association of miR-192-5p with atherosclerosis and its effect on proliferation and migration of vascular smooth muscle cells","volume":"63","author":"Zhao","year":"2021","journal-title":"Mol. Biotechnol."},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb1275","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1007\/s12035-021-02332-x","article-title":"Long non-coding RNA GAS5 worsens coronary atherosclerosis through microRNA-194-3p\/TXNIP axis","volume":"58","author":"Li","year":"2021","journal-title":"Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.vph.2023.107249_bb1280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145930","article-title":"miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease","volume":"10","author":"Schulte","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb1285","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12033-021-00323-w","article-title":"MicroRNA-199a-3p exhibits beneficial effects in asymptomatic atherosclerosis by inhibiting vascular smooth muscle cell proliferation and migration","volume":"63","author":"Sun","year":"2021","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.vph.2023.107249_bb1290","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3389\/fimmu.2020.00907","article-title":"MicroRNA-200a inhibits inflammation and atherosclerotic lesion formation by disrupting EZH2-mediated methylation of STAT3","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1295","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10557-020-06935-9","article-title":"MicroRNA-205-5p promotes unstable atherosclerotic plaque formation in vivo","volume":"34","author":"Meng","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.vph.2023.107249_bb1300","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/354517","article-title":"Human miR-221\/222 in physiological and atherosclerotic vascular remodeling","volume":"2015","author":"Chistiakov","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb1305","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23608","article-title":"Overexpressed miR-335-5p reduces atherosclerotic vulnerable plaque formation in acute coronary syndrome","volume":"35","author":"Sun","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1310","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112507","article-title":"MiR-375 silencing attenuates pro-inflammatory macrophage response and foam cell formation by targeting KLF4","volume":"400","author":"Qiu","year":"2021","journal-title":"Exp. Cell Res."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb1315","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20182016","article-title":"Circulating microRNA-378 levels serve as a novel biomarker for assessing the severity of coronary stenosis in patients with coronary artery disease","volume":"39","author":"Li","year":"2019","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/17085381211058571","article-title":"Diagnostic and prognostic significance of miR-451a in patients with atherosclerosis","volume":"31","author":"Wang","year":"2023","journal-title":"Vascular"},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1325","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.celrep.2013.12.015","article-title":"Regulation of the apolipoprotein gene cluster by a long noncoding RNA","volume":"6","author":"Halley","year":"2014","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb1330","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2015.05.124","article-title":"Long non-coding RNA APTR promotes the activation of hepatic stellate cells and the progression of liver fibrosis","volume":"463","author":"Yu","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb1335","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1111\/jcmm.14987","article-title":"Epigenetic silencing of LncRNA ANRIL enhances liver fibrosis and HSC activation through activating AMPK pathway","volume":"24","author":"Yang","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.vph.2023.107249_bb1340","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110190","article-title":"LncRNA HOTAIR regulates the lipid accumulation in non-alcoholic fatty liver disease via miR-130b-3p\/ROCK1 axis","volume":"90","author":"Guo","year":"2022","journal-title":"Cell. Signal."},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb1345","doi-asserted-by":"crossref","first-page":"18169","DOI":"10.1002\/jcp.28450","article-title":"Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease","volume":"234","author":"Shen","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1350","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbrc.2018.03.127","article-title":"Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt\/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis","volume":"499","author":"Zhang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb1355","article-title":"The role of long non-coding RNAs (lncRNAs) in the development and progression of fibrosis associated with nonalcoholic fatty liver disease (NAFLD)","volume":"4","author":"Hanson","year":"2018","journal-title":"Noncoding RNA"},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1360","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1038\/s41467-018-05383-2","article-title":"Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis","volume":"9","author":"Zhao","year":"2018","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb1365","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7150\/ijbs.16635","article-title":"Identification of a novel human long non-coding RNA that regulates hepatic lipid metabolism by inhibiting SREBP-1c","volume":"13","author":"Li","year":"2017","journal-title":"Int. J. Biol. Sci."},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb1370","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181722","article-title":"LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a\/PPARgamma axis in non-alcoholic fatty liver disease","volume":"39","author":"Liu","year":"2019","journal-title":"Biosci. Rep."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb1375","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cmet.2015.02.004","article-title":"A liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice","volume":"21","author":"Li","year":"2015","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1380","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1038\/s41598-017-03175-0","article-title":"TGF-beta-induced hepatocyte lincRNA-p21 contributes to liver fibrosis in mice","volume":"7","author":"Tu","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb1385","first-page":"455","article-title":"Down-regulation of LncRNA UCA1 alleviates liver injury in rats with liver cirrhosis","volume":"12","author":"Zhu","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb1390","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11010-022-04506-0","article-title":"LncRNA XIST promotes mitochondrial dysfunction of hepatocytes to aggravate hepatic fibrogenesis via miR-539-3p\/ADAMTS5 axis","volume":"478","author":"Wu","year":"2023","journal-title":"Mol. Cell. Biochem."},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb1395","article-title":"Plasma long noncoding RNA LeXis is a potential diagnostic marker for non-alcoholic steatohepatitis","volume":"10","author":"Park","year":"2020","journal-title":"Life (Basel)"},{"key":"10.1016\/j.vph.2023.107249_bb1400","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.trsl.2017.09.001","article-title":"Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells","volume":"190","author":"Leti","year":"2017","journal-title":"Transl. Res."},{"key":"10.1016\/j.vph.2023.107249_bb1405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2019.01.018","article-title":"LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6","volume":"94","author":"Huang","year":"2019","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb1410","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.bbrc.2019.11.015","article-title":"LncRNA Meg8 suppresses activation of hepatic stellate cells and epithelial-mesenchymal transition of hepatocytes via the Notch pathway","volume":"521","author":"Chen","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.vph.2023.107249_bb1415","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.gene.2019.02.096","article-title":"Long noncoding RNA Mirt2 upregulates USP10 expression to suppress hepatic steatosis by sponging miR-34a-5p","volume":"700","author":"Zhang","year":"2019","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1420","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s42003-023-04670-z","article-title":"LncRNA-MIAT activates hepatic stellate cells via regulating Hippo pathway and epithelial-to-mesenchymal transition","volume":"6","author":"Zhan","year":"2023","journal-title":"Commun. Biol."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb1425","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/jcb.26317","article-title":"Down-regulation of lncRNA-NEAT1 alleviated the non-alcoholic fatty liver disease via mTOR\/S6K1 signaling pathway","volume":"119","author":"Wang","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb1430","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1080\/21655979.2022.2037841","article-title":"Long non-coding RNA-non-coding RNA activated by DNA damage inhibition suppresses hepatic stellate cell activation via microRNA-495-3p\/sphingosine 1-phosphate receptor 3 axis","volume":"13","author":"Zou","year":"2022","journal-title":"Bioengineered"},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1435","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1159\/000496012","article-title":"Long noncoding RNA HOTTIP promotes mouse hepatic stellate cell activation via downregulating miR-148a","volume":"51","author":"Li","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.vph.2023.107249_bb1440","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.omtn.2019.05.026","article-title":"Loss of lncRNA-SNHG7 promotes the suppression of hepatic stellate cell activation via miR-378a-3p and DVL2","volume":"17","author":"Yu","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb1445","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.bbrc.2018.07.054","article-title":"TUG1 is involved in liver fibrosis and activation of HSCs by regulating miR-29b","volume":"503","author":"Han","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"39","key":"10.1016\/j.vph.2023.107249_bb1450","doi-asserted-by":"crossref","first-page":"62886","DOI":"10.18632\/oncotarget.11709","article-title":"Long non-coding RNA PVT1 activates hepatic stellate cells through competitively binding microRNA-152","volume":"7","author":"Zheng","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb1455","doi-asserted-by":"crossref","DOI":"10.3390\/cells8101277","article-title":"Increased expression of RUNX1 in liver correlates with NASH activity score in patients with non-alcoholic steatohepatitis (NASH)","volume":"8","author":"Kaur","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.vph.2023.107249_bb1460","doi-asserted-by":"crossref","first-page":"35531","DOI":"10.1038\/srep35531","article-title":"LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL)","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb1465","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/liv.14167","article-title":"Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity","volume":"39","author":"Di Mauro","year":"2019","journal-title":"Liver Int."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb1470","doi-asserted-by":"crossref","DOI":"10.3390\/genes11050545","article-title":"Expression of the long noncoding RNA GAS5 correlates with liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"11","author":"Han","year":"2020","journal-title":"Genes (Basel)"},{"issue":"17","key":"10.1016\/j.vph.2023.107249_bb1475","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1080\/15384101.2021.1951940","article-title":"LncRNA APOA1-AS facilitates proliferation and migration and represses apoptosis of VSMCs through TAF15-mediated SMAD3 mRNA stabilization","volume":"20","author":"Wang","year":"2021","journal-title":"Cell Cycle"},{"issue":"12","key":"10.1016\/j.vph.2023.107249_bb1480","doi-asserted-by":"crossref","first-page":"19858","DOI":"10.1002\/jcb.29291","article-title":"Long noncoding RNA Alu-mediated p21 transcriptional regulator promotes proliferation, migration, and pipe-formation of human microvascular endothelial cells by sponging miR-126","volume":"120","author":"Song","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb1485","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/jcpt.13060","article-title":"ANRIL and atherosclerosis","volume":"45","author":"Chen","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb1490","doi-asserted-by":"crossref","DOI":"10.5808\/GI.2018.16.4.e25","article-title":"Circulating HOTAIR RNA is potentially up-regulated in coronary artery disease","volume":"16","author":"Avazpour","year":"2018","journal-title":"Genomics Inform."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1495","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/dna.2015.3203","article-title":"Long noncoding RNA highly upregulated in liver cancer regulates the tumor necrosis factor-alpha-induced apoptosis in human vascular endothelial cells","volume":"35","author":"Ma","year":"2016","journal-title":"DNA Cell Biol."},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb1500","first-page":"1067","article-title":"Balectin-3 affects the stability of vulnerable coronary atherosclerosis plaques by targeted modulation of lncARSR","volume":"41","author":"Xu","year":"2021","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb1505","first-page":"4222","article-title":"TGF-beta1 upregulates the expression of lncRNA-ATB to promote atherosclerosis","volume":"19","author":"Yu","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.vph.2023.107249_bb1510","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fneur.2019.00032","article-title":"Long noncoding RNA-H19 contributes to atherosclerosis and induces ischemic stroke via the upregulation of acid phosphatase 5","volume":"10","author":"Huang","year":"2019","journal-title":"Front. Neurol."},{"issue":"17","key":"10.1016\/j.vph.2023.107249_bb1515","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1161\/CIRCULATIONAHA.114.011675","article-title":"LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity","volume":"130","author":"Wu","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1520","doi-asserted-by":"crossref","first-page":"20230738","DOI":"10.1515\/med-2023-0738","article-title":"lncRNA UCA1 regulates miR-132\/Lrrfip1 axis to promote vascular smooth muscle cell proliferation","volume":"18","author":"Chen","year":"2023","journal-title":"Open Med. (Wars)"},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb1525","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10753-020-01391-x","article-title":"LncRNA XIST promotes atherosclerosis by regulating miR-599\/TLR4 axis","volume":"44","author":"Yang","year":"2021","journal-title":"Inflammation"},{"issue":"19","key":"10.1016\/j.vph.2023.107249_bb1530","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.jacc.2018.08.2161","article-title":"Long noncoding RNAs in atherosclerosis: JACC review topic of the week","volume":"72","author":"Zhang","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb1535","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/FJC.0000000000001061","article-title":"Long noncoding RNA MALAT1 regulates the progression of atherosclerosis by miR-330-5p\/NF-kappaB signal pathway","volume":"78","author":"Shi","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"7","key":"10.1016\/j.vph.2023.107249_bb1540","first-page":"3326","article-title":"Long noncoding RNA MEG3 suppressed endothelial cell proliferation and migration through regulating miR-21","volume":"9","author":"Wu","year":"2017","journal-title":"Am. J. Transl. Res."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1545","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbrc.2019.01.074","article-title":"LncRNA MEG8 regulates vascular smooth muscle cell proliferation, migration and apoptosis by targeting PPARalpha","volume":"510","author":"Zhang","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1550","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41467-017-02229-1","article-title":"The LPS-inducible lncRNA Mirt2 is a negative regulator of inflammation","volume":"8","author":"Du","year":"2017","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.vph.2023.107249_bb1555","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1161\/CIRCULATIONAHA.120.052023","article-title":"Long noncoding RNA MIAT controls advanced atherosclerotic lesion formation and plaque destabilization","volume":"144","author":"Fasolo","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1560","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1161\/ATVBAHA.123.319251","article-title":"Exercise mitigates endothelial pyroptosis and atherosclerosis by downregulating NEAT1 through N6-methyladenosine modifications","volume":"43","author":"Yang","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2023.107249_bb1565","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.701628","article-title":"LncRNA NORAD promotes vascular endothelial cell injury and atherosclerosis through suppressing VEGF gene transcription via enhancing H3K9 deacetylation by recruiting HDAC6","volume":"9","author":"Kai","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb1570","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/jcb.26448","article-title":"Long noncoding RNA HOTTIP promotes endothelial cell proliferation and migration via activation of the Wnt\/beta-catenin pathway","volume":"119","author":"Liao","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.vph.2023.107249_bb1575","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118013","article-title":"E2F1\/SNHG7\/miR-186-5p\/MMP2 axis modulates the proliferation and migration of vascular endothelial cell in atherosclerosis","volume":"257","author":"Zhang","year":"2020","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb1580","first-page":"972","article-title":"lncRNA TUG1 promotes atherosclerosis progression by targeting miR-382-5p","volume":"14","author":"Shi","year":"2021","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"21","key":"10.1016\/j.vph.2023.107249_bb1585","doi-asserted-by":"crossref","first-page":"24449","DOI":"10.18632\/aging.203696","article-title":"Small interfering RNA-induced silencing lncRNA PVT1 inhibits atherosclerosis via inactivating the MAPK\/NF-kappaB pathway","volume":"13","author":"Du","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb1590","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/cvr\/cvaa034","article-title":"RUNX1: an emerging therapeutic target for cardiovascular disease","volume":"116","author":"Riddell","year":"2020","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1595","first-page":"5207","article-title":"LncRNA SRA deregulation contributes to the development of atherosclerosis by causing dysfunction of endothelial cells through repressing the expression of adipose triglyceride lipase","volume":"18","author":"Yang","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"21","key":"10.1016\/j.vph.2023.107249_bb1600","doi-asserted-by":"crossref","first-page":"22335","DOI":"10.18632\/aging.103786","article-title":"LncRNA-modulated autophagy in plaque cells: a new paradigm of gene regulation in atherosclerosis?","volume":"12","author":"Ren","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1605","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-0043-118666","article-title":"Pivotal role of TNF-alpha in the development and progression of nonalcoholic fatty liver disease in a murine model","volume":"50","author":"Kakino","year":"2018","journal-title":"Horm. Metab. Res."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1610","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrcardio.2009.57","article-title":"Role for TNF in atherosclerosis? Lessons from autoimmune disease","volume":"6","author":"McKellar","year":"2009","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.vph.2023.107249_bb1615","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2020.06.005","article-title":"Ikk2-mediated inflammatory activation of arterial endothelial cells promotes the development and progression of atherosclerosis","volume":"307","author":"Mussbacher","year":"2020","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb1620","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/hep.25711","article-title":"Hepatic activation of IKK\/NFkappaB signaling induces liver fibrosis via macrophage-mediated chronic inflammation","volume":"56","author":"Sunami","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.vph.2023.107249_bb1625","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/472432","article-title":"Roles for PI3K\/AKT\/PTEN pathway in cell signaling of nonalcoholic fatty liver disease","volume":"2013","author":"Matsuda","year":"2013","journal-title":"ISRN Endocrinol."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1630","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cmet.2007.10.007","article-title":"Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease","volume":"6","author":"Fernandez-Hernando","year":"2007","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1635","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.03.019","article-title":"Cdc42 and Rac1 are major contributors to the saturated fatty acid-stimulated JNK pathway in hepatocytes","volume":"56","author":"Sharma","year":"2012","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.vph.2023.107249_bb1640","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1161\/ATVBAHA.119.313832","article-title":"Statins disrupt macrophage Rac1 regulation leading to increased atherosclerotic plaque calcification","volume":"40","author":"Healy","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.vph.2023.107249_bb1645","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201810124","article-title":"Liver ASK1 protects from non-alcoholic fatty liver disease and fibrosis","volume":"11","author":"Challa","year":"2019","journal-title":"EMBO Mol. Med."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb1650","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/ATVBAHA.121.316662","article-title":"Major vault protein prevents atherosclerotic plaque destabilization by suppressing macrophage ASK1-JNK signaling","volume":"42","author":"Liu","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2023.107249_bb1655","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155213","article-title":"Vascular smooth muscle cell c-Fos is critical for foam cell formation and atherosclerosis","volume":"132","author":"Miao","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.vph.2023.107249_bb1660","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.597449","article-title":"MicroRNA-29c acting on FOS plays a significant role in nonalcoholic steatohepatitis through the interleukin-17 signaling pathway","volume":"12","author":"Cai","year":"2021","journal-title":"Front. Physiol."},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb1665","doi-asserted-by":"crossref","first-page":"E1395","DOI":"10.1073\/pnas.1621188114","article-title":"Targeting IRE1 with small molecules counteracts progression of atherosclerosis","volume":"114","author":"Tufanli","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"530","key":"10.1016\/j.vph.2023.107249_bb1670","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aao4617","article-title":"IRE1alpha prevents hepatic steatosis by processing and promoting the degradation of select microRNAs","volume":"11","author":"Wang","year":"2018","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1675","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010017","article-title":"The IL-1 family and its role in atherosclerosis","volume":"24","author":"Gonzalez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb1680","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.molmed.2018.03.005","article-title":"IL-1 family cytokine pathways underlying NAFLD: towards new treatment strategies","volume":"24","author":"Mirea","year":"2018","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.vph.2023.107249_bb1685","article-title":"Role of PI3K in the progression and regression of atherosclerosis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb1690","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jhep.2011.01.048","article-title":"Lack of interleukin-1alpha or interleukin-1beta inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice","volume":"55","author":"Kamari","year":"2011","journal-title":"J. Hepatol."},{"issue":"34","key":"10.1016\/j.vph.2023.107249_bb1695","doi-asserted-by":"crossref","first-page":"12279","DOI":"10.1074\/jbc.REV120.011356","article-title":"From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases","volume":"295","author":"Zhao","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.vph.2023.107249_bb1700","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1038\/s41467-018-07132-x","article-title":"PRKAA1\/AMPKalpha1-driven glycolysis in endothelial cells exposed to disturbed flow protects against atherosclerosis","volume":"9","author":"Yang","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.vph.2023.107249_bb1705","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/CIRCULATIONAHA.109.900928","article-title":"Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo","volume":"121","author":"Dong","year":"2010","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.vph.2023.107249_bb1710","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/CIRCRESAHA.110.233841","article-title":"Disturbed blood flow induces RelA expression via c-Jun N-terminal kinase 1: a novel mode of NF-kappaB regulation that promotes arterial inflammation","volume":"108","author":"Cuhlmann","year":"2011","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.vph.2023.107249_bb1715","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.26068","article-title":"Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune response","volume":"57","author":"Moles","year":"2013","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.vph.2023.107249_bb1720","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/s41418-018-0239-8","article-title":"The transcription factor c-Jun\/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating osteopontin expression","volume":"26","author":"Schulien","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.vph.2023.107249_bb1725","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.redox.2014.02.007","article-title":"Potential role of proteasome on c-Jun related signaling in hypercholesterolemia induced atherosclerosis","volume":"2","author":"Sozen","year":"2014","journal-title":"Redox Biol."},{"issue":"5","key":"10.1016\/j.vph.2023.107249_bb1730","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.ATV.0000160340.72641.87","article-title":"Nuclear factor kappaB signaling in atherogenesis","volume":"25","author":"de Winther","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.vph.2023.107249_bb1735","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1042\/CS20120289","article-title":"NF-kappaB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses","volume":"124","author":"Locatelli","year":"2013","journal-title":"Clin. Sci. (Lond.)"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912300109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912300109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T03:05:30Z","timestamp":1724641530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153718912300109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":347,"alternative-id":["S153718912300109X"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2023.107249","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2023.107249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107249"}}